Sanofi wins FDA approval for neurological symptoms of type 3 Gaucher disease
FDA approval of venglustat (Infilbray) provides a new oral, brain-penetrating option for neurological symptoms of type 3 Gaucher disease. Evidence came from a 43-patient Phase 3 comparison with significant improvement on a combined neurological test at 52 weeks; longer-term outcomes and safety warnings remain follow-up questions.
Sources (3)
Updated Nov 20, 2026